Almirall, S.A.

Equities

ALM

ES0157097017

Pharmaceuticals

Market Closed - BME 11:35:01 2024-04-23 am EDT 5-day change 1st Jan Change
8.36 EUR +1.46% Intraday chart for Almirall, S.A. +2.83% -0.77%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment MT
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB... Our Logo
Almirall: share price surges after agreement with Novo Nordisk CF
Transcript : Almirall, S.A., 2023 Earnings Call, Feb 19, 2024
Almirall Secures Global Rights for Blocking Monoclonal Antibody Under Deal with Novo Nordisk MT
Almirall S.A. Enters into an Exclusive License Agreement with Novo Nordisk CI
Almirall, S.A. Provides Earnings Guidance for the Year 2024 CI
Almirall, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Almirall, S.A. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:00 AM
Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases CI
Almirall: messenger RNA alliance with Belgium's etherna CF
Almirall Collaborates with etherna on Development of Severe Skin Disease Therapies MT
Almirall and Etherna Enter into A Multi-Target Alliance to Develop mRNA-Based Therapies in Medical Dermatology CI
Certain Shares of Almirall, S.A. are subject to a Lock-Up Agreement Ending on 10-DEC-2023. CI
Almirall: share price rises, EU green light for eczema treatment CF
European Commission Approves Almirall’s Skin Disease Drug MT
Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic Dermatitis CI
Almirall Teams Up with Absci on AI-designed Dermatological Disease Treatments MT
Sector Update: Health Care Stocks Advance Premarket Tuesday MT
Absci Enters AI Drug Discovery Pact With Almirall to Develop New Therapies for Dermatological Diseases; Shares Surge Premarket MT
Transcript : Almirall, S.A., Nine Months 2023 Earnings Call, Nov 09, 2023
Almirall, S.A. Revises Earnings Guidance for the Year 2023 CI
Almirall, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Almirall’s Eczema Drug Shows Clinical Improvements in Adults, Adolescents MT
Almirall Signs Licensing Deal With EpimAb for Bispecific Antibodies Development MT
Chart Almirall, S.A.
More charts
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
8.36 EUR
Average target price
11.28 EUR
Spread / Average Target
+34.95%
Consensus
  1. Stock Market
  2. Equities
  3. ALM Stock
  4. News Almirall, S.A.
  5. Almirall Secures Global Licensing Deal With Ichnos Sciences For Potential Autoimmune Disease Treatment